Top

Published in:

01-02-2012 | Original article

Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation

Authors: C. Blattmann, M.D., S. Oertel, M. Thiemann, K.J. Weber, P. Schmezer, O. Zelezny, R. Lopez Perez, A.E. Kulozik, J. Debus, V. Ehemann

Published in: Strahlentherapie und Onkologie | Issue 2/2012

Abstract

Purpose

Osteosarcoma and atypical teratoid rhabdoid tumors are tumor entities with varying response to common standard therapy protocols. Histone acetylation affects chromatin structure and gene expression which are considered to influence radiation sensitivity. The aim of this study was to investigate the effect of the combination therapy with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and irradiation on atypical teratoid rhabdoid tumors and osteosarcoma compared to normal tissue cell lines.

Methods

Clonogenic assay was used to determine cell survival. DNA double-strand breaks (DSB) were examined by pulsed-field electrophoresis (PFGE) as well as by γH2AX immunostaining involving flow cytometry, fluorescence microscopy, and immunoblot analysis.

Results

SAHA lead to an increased radiosensitivity in tumor but not in normal tissue cell lines. γH2AX expression as an indicator for DSB was significantly increased when SAHA was applied 24 h before irradiation to the sarcoma cell cultures. In contrast, γH2AX expression in the normal tissue cell lines was significantly reduced when irradiation was combined with SAHA. Analysis of initial DNA fragmentation and fragment rejoining by PFGE, however, did not reveal differences in response to the SAHA pretreatment for either cell type.

Conclusion

SAHA increases radiosensitivity in tumor but not normal tissue cell lines. The increased H2AX phosphorylation status of the SAHA-treated tumor cells post irradiation likely reflects its delayed dephosphorylation within the DNA damage signal decay rather than chromatin acetylation-dependent differences in the overall efficacy of DSB induction and rejoining. The results support the hypothesis that combining SAHA with irradiation may provide a promising strategy in the treatment of solid tumors.

Available only for authorised users

Baschnagel A, Russo A, Burgan WE et al (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8:1589–1595PubMedCrossRef

Biade S, Stobbe CC, Boyd JT et al (2001) Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 77:1033–1042PubMedCrossRef

Blattmann C, Oertel S, Ehemann V et al (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237–245PubMedCrossRef

Camphausen K, Burgan W, Cerra M et al (2004) Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316–321PubMedCrossRef

Chen X, Wong J, Wong P et al (2011) Low dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 9:448–461PubMedCrossRef

Chinnaiyan P, Vallabhaneni G, Armstrong E et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223–229PubMedCrossRef

Chung YL, Lee MY, Pui NN (2009) Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30:1387–1397PubMedCrossRef

Furchert SE, Lanvers-Kaminsky C, Jürgens H et al (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787–1794PubMedCrossRef

Huang X, Darzynkiewicz Z (2006) Cytometric assessment of histone H2AX phosphorylation. Methods Mol Biol 314:73–80PubMedCrossRef

10.

Jeggo PA (1998) Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 150:80–91CrossRef

11.

Kaatsch P, Debling D, Blettner M et al (2009) Second malignant neoplasms after childhood cancer in Germany—results from the long-term follow-up of the German childhood cancer registry. Strahlenther Onkol 185:8–10PubMedCrossRef

12.

Kappler M, Taubert H, Bartel F et al (2005) Radiosensitization after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13:167–172PubMed

13.

Karagiannis TC, Kn H, El-Osta A (2006) The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1:131–137PubMedCrossRef

14.

Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247–254PubMedCrossRef

15.

Klenke FM, Abdollahi A, Bischof M et al (2011) Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol 187:45–51PubMedCrossRef

16.

Lee M-J, Kim YS, Kummar S et al (2008) Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20:639–649PubMedCrossRef

17.

Levesque AA, Fanous AA, Poh A et al (2008) Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 7:252–262PubMedCrossRef

18.

MacPhail SH, Banath JP, Yu Y et al (2003) Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res 159:759–767PubMedCrossRef

19.

Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210–1216PubMedCrossRef

20.

Minucci S, Pelicci P (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRef

21.

Munshi A, Tanaka T, Hobbs ML et al (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5:1967–1974PubMedCrossRef

22.

Niermann KJ, Moretti L, Giacalone NJ (2011) Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated aurora kinase B inhibition. Radiat Res 175:444–451PubMedCrossRef

23.

O’Connor OA, Heaney ML, Schwartz L et al (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166–173CrossRef

24.

Patties I, Jahns J, Hildebrandt G et al (2009) Additive effects of 5-aza-2’-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Strahlenther Onkol 185:331–338PubMedCrossRef

25.

Paull TT, Rogakou EP, Yamazaki V et al (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10:886–895PubMedCrossRef

26.

Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59:928–942PubMedCrossRef

27.

Purrucker JC, Fricke A, Ong MF et al (2010) HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. Oncol Rep 23:263–269PubMed

28.

Rudat V, Bachmann N, Kuepper JH et al (2001) Overexpression of the DNA-binding domain of poly (ADP-ribose) polymerase inhibits rejoining of ionizing radiation-induced DNA-double-strand breaks. Int J Radiat Biol 77:303–307PubMedCrossRef

29.

Weiss C, Grabenbauer GG, Sauer R et al (2003) Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Strahlenther Onkol 179:93–98PubMedCrossRef

30.

Welte B, Suhr P, Bootke D et al (2010) Second malignancies in high-dose areas of previous tumor radiotherapy. Strahlenther Onkol 186:174–179PubMedCrossRef

31.

Wolff HA, Hennies S, Herrmann MK et al (2011) Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer. Strahlenther Onkol 187:52–58PubMedCrossRef

32.

Zhang Y, Jung M, Dritschilo A et al (2005) Enhancement of radiation sensitivity of human squamous cells by histone deacetylase inhibition. Radiat Res 163:488–493CrossRef

Title: Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation
Authors: C. Blattmann, M.D.
S. Oertel
M. Thiemann
K.J. Weber
P. Schmezer
O. Zelezny
R. Lopez Perez
A.E. Kulozik
J. Debus
V. Ehemann
Publication date: 01-02-2012
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-0028-5

At a glance: The STEP trials

Springer Medicine

Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2012

Capecitabin plus Oxaliplatin verglichen mit Fluorouracil und Folinsäure als adjuvante Therapie bei Kolonkarzinom im Stadium III

Breast cancer and funnel chest

Numerical deconvolution to enhance sharpness and contrast of portal images for radiotherapy patient positioning verification

Dosimetric integration of daily mega-voltage cone-beam CT for image-guided intensity-modulated radiotherapy

Regionäre Lymphknoten, Satelliten und TNM: Werden wir besser?

Trotz geringer dosislimitierender Toxizität ist Vorsicht bei der extrem hypofraktionierten Dosiseskalation mithilfe Körperstereotaxie (SBRT) bei frühen Prostatakarzinomen mit niedrigem oder intermediärem Risikoprofil geboten